Iqvia price target raised to $280 from $270 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Iqvia to $280 from $270 and keeps an Overweight rating on the shares after a “modest beat” in Q2 that was led by better-than-expected TAS performance. Though customer spending caution remains, tangibly improved decision timelines and resumption of delayed projects increase visibility into a TAS recovery, the analyst tells investors.